Introduction
With the increasing morbidity and mortality imposed by cancers, approaches that could improve the outcome of existing treatment modalities are of signicance.
1 Surgical resection is a mainstay for solid tumor treatment, whereupon residual tumors due to incomplete resection oen result in tumor relapse. The utility of uorescence guided surgery is demonstrated by recent clinical treatment of ovarian cancer with the aid of uorescein-conjugated folate.
2 Recently, optical agents that could direct surgeons to tumor foci evasive to visual inspection have been intensively explored.
2,3
High tumor-to-background signal contrast is paramount for tumor imaging. As such, optical probes that could be activated to a "signal-on" state within tumors while remaining silent in off-target settings are critical to achieve low background signals.
3,4 Rhodamine derivatives with intramolecular spirorings are poised for proton-triggered uorogenic opening of the intramolecular rings within acidic lysosomes, enabling high performance tumor imaging in mice models. 5 Relative to rhodamines, near-infrared (NIR) dyes are advantageous for in vivo imaging as biological tissues display the least optical absorption and autouorescence in the NIR window (650-900 nm). 6 Nanomaterials that could convert NIR irradiation into cytotoxic heat are being actively explored for photothermal cancer therapy.
7 Given concerns regarding the biosafety of nanomaterials, small molecular NIR dyes could be biocompatible. For instance, indocyanine green (ICG) has been approved for clinical applications. 8 Analogous to acid-responsive rhodamines, probes displaying lysosomal acidity-activatable NIR uorescence and photothermal properties have been largely unexplored for intraoperative tumor therapy.
To achieve the high tumor-to-background signal contrast required for in vivo tumor imaging, dyes are oen deliberately armed with tumor-homing entities, such as monoclonal antibodies, folates, aptamers, etc.
9 Sialic acids (SA) are anionic monosaccharides commonly located at termini of cell surface glycans, 10 and hypersialylation of cell surface constituents has been identied in a broad spectrum of cancers, 11 suggesting enhanced metabolic demand for SA by these tumors cells. Fluorescein isothiocyanate-labelled sialic acid (SA-FITC) was recently employed for high performance tumor detection in mice, showing effective uptake of SA monosaccharide by metabolically active tumor cells.
12 Albeit selectively accumulated in tumors, SA-FITC suffers from "always-on" green uo-rescence which has limited tissue penetration, and quick in vivo clearance which might lead to fast attenuation of tumor-associated signals during surgery. 12 Herein, we report a sialylated pH-activatable NIR prouorophore (SA-pNIR) for targeted tumor imaging and photothermal therapy in mice with dramatically improved pharmacokinetics critical for clinical translation. SA-pNIR consists of a sialic acid entity for effective in vivo tumor uptake and an activatable NIR prouorophore which becomes photothermal and uorescent within acidic lysosomes.
Results and discussion
Acidic pH mediated uorescence activation of SA-pNIR Optical probes with turn-on uorescence inside tumors while being silent in off-target settings are benecial for low-background tumor imaging.
3, 4 We recently reported the use of rhodamines with intramolecular spirorings for in vivo tumor detection via lysosomal acidity-triggered uorogenic opening of the rings to give rhodamines.
5 Relative to red-emissive rhodamines, NIR dyes are advantageous for bioimaging due to the enhanced tissue penetration of NIR uorescence and the minimal light absorption and autouorescence of biological tissues in the NIR region. 6 Hence, we set out to develop a NIR probe, akin to rhodamine-lactams, for tumor imaging via lysosomal acidity-mediated uorescence activation within tumors (Fig. 1B) .
(
, a NIR dye reported by Lin et al., 13 was rst amidated with ethylenediamine and then conjugated with 9-amino-9-deoxy-5-N-acetylneuraminic acid to afford the desired SA-pNIR in 32% overall yield (ESI †). To probe its pH responsiveness, SA-pNIR was spiked into buffers of pH 4.0-8.0 and the uorescence emission and UV-vis-NIR absorption of the solutions were recorded over the buffer pH range. As shown in Fig. 2 , SA-pNIR exhibits NIR absorption and uorescence emission in acidic media, proving the proton-mediated isomerization of SA-pNIR into uorescent SA-NIR as shown in Fig. 1B . pH titration shows that SA-pNIR is weakly uorescent at cytosolic pH (pH 7.2) and yet exhibits enhanced uorescence at pH 4.5-6.0, which ideally matches the lysosomal pH window (pH 4-6). These results indicate the applicability of SA-pNIR to illuminating acidic lysosomes in living cells.
Illumination of acidic lysosomes in cells by SA-pNIR
Lysosomes are the major intracellular acidic compartments and the number and acidity of lysosomes could be signicantly boosted in cancer cells.
14 To determine the performance of intracellular signal activation, HeLa cells, U87-MG cells and Raw 264.7 cells were cultured in Dulbecco's Modied Eagle's Medium (DMEM) supplemented with SA-pNIR and then stained with LysoTracker Green DND-26, referred to herein as Lysotracker green. Confocal microscopy images show that NIR uorescence is clearly observed within all the three cell lines tested and colocalizes with Lysotracker green specic for acidic lysosomes (Fig. 3) . The colocalization conrms that SA-pNIR could be taken up by these cells and then activated to uores-cent SA-NIR within lysosomes. To probe cellular uptake kinetics, HeLa, U87-MG and Raw 264.7 cells were loaded with SA-pNIR and then stained with DiI specic for plasma membranes. The intracellular NIR signals were determined aer incubation for 1 h, 4 h and 24 h. It was revealed that the intracellular NIR uorescence intensied upon prolonged incubation (Fig. S1 , ESI †), suggesting continuous uptake of SApNIR from the surrounding medium by these cell lines.
To assess the dependence of intracellular NIR uorescence on lysosomal acidity, we measured SA-pNIR signals in cells treated with Balomycin A1 (BFA), which is a potent inhibitor of V-ATPase and effectively alkalinizes lysosomes in BFA-treated cells. 15 As shown in Fig. 4 , the intracellular signals of SA-pNIR largely vanished in HeLa, U87-MG and Raw 264.7 cells pretreated with BFA compared to the cells in the absence of BFA. The BFA-and SA-pNIR treated cells that displayed markedly decreased NIR signals within the cells were further incubated in a phosphate buffer of pH 4.0. Fig. 4 revealed the recovery of intense intracellular NIR signals in the aforementioned HeLa, U87-MG and Raw 264.7 cells in acidic buffer, excluding the loss of intracellular SA-pNIR in BFA-treated cells and further conrming the lysosomal pH dependent "turn-on" uorescence of SA-pNIR in cells. Solid tumors are hallmarked by acidic microenvironments due to metabolically accumulated lactic acid.
16
The acidic microenvironment has been widely targeted for tumor therapy and imaging. The recovered NIR uorescence of BFA-treated cells in acidic buffer strongly indicates that the acidic tumor microenvironments and tumor lysosomes might exert synergistic effects on signal activation of SA-pNIR endocytosed into tumor cells in vivo.
Illumination of subcutaneous tumors in mice with SA-pNIR
Shown to uoresce in lysosomes, SA-pNIR was further evaluated for its efficacy and selectivity in illuminating subcutaneous tumors in mice. Nude or ICR mice were inoculated subcutaneously with H22 hepatocellular carcinoma cells and then maintained for 5-10 days to allow the development of tumor xenogras. SA-pNIR were intravenously administered into the tumor-bearing nude mice via tail vein. The mice were imaged for whole body NIR uorescence over the course of 144 h aer injection. No NIR signal was observed in mice 30 min aer administration (Fig. 5) , demonstrating that SA-pNIR remained silent during circulation in the blood stream (pH 7.4). Intense NIR uorescence was identied in subcutaneous tumors at 48 h postinjection and the signal contrast between tumor and normal tissues remained high up to 144 h postinjection (Fig. 5) . The tumor-associated uorescence validates that SA-pNIR is effectively accumulated in tumors, where it is activated to the "signal-on" state. To further determine the biodistribution of SA-pNIR in subcutaneous tumors and healthy tissues, the tumor and representative organs were dissected from tumor-bearing ICR mice pretreated with SA-pNIR for 48 h and then probed by ex vivo uorescence analysis. Consistently, intense signals were observed in the tumor whereas moderate to low levels of NIR uorescence were present in the kidney, heart, spleen, lung and liver (Fig. 6B) , validating effective tumor uptake and activation of SA-pNIR within tumors. The liver-and kidney-associated NIR uorescence suggests renal and hepatic clearance of injected SA-pNIR, which is benecial for clinical translation. Collectively, these data conrm preferential in vivo tumoral uptake of SA-pNIR and ensuing uorescence activation of SA-pNIR, which correlate well with the aforementioned whole body imaging studies (Fig. 5) .
In previous tumor imaging studies, the uorescence of SA-FITC within tumors reached maxima at 20 min postinjection and then quickly decreased by 80% at 1 h postinjection.
12 The long-term retention of SA-pNIR within tumors together with the preferential tumor accumulation of SA-pNIR and the high tumor-to-healthy tissue signal ratios suggest the potential utility of SA-pNIR for low background intraoperative tumor detection.
To probe the impact of the sialic acid domain of SA-pNIR on in vivo tumor targeting, D-glucosamine conjugated with the NIR prouorophore (Glu-pNIR) was prepared and then administered into tumor-bearing ICR mice via tail vein (ESI †). In contrast with mice treated with SA-pNIR, whole body imaging revealed no signicant NIR signal in subcutaneous tumors from mice treated with Glu-pNIR at 48 and 144 h postinjection (Fig. 7 and S3, ESI †), demonstrating the critical role of sialic acid for tumor targeting. Historically, monoclonal antibodies, folates, peptides and aptamers have oen been used to direct dyes to target tumors.
9 The demonstrated high performance tumor illumination with SA-pNIR shows that sialic acid with a C-9 conjugated theranostic entity is an attractive warhead for targetable cancer imaging. Hypersialylation of cell surface glycoconjugates is a hallmark of a broad spectrum of cancers 11 and oen correlates with their metastatic potentials.
17 The tumor-associated over-sialylation suggests enhanced metabolic demand for SA by tumors. Historically, metabolic engineering of cell surface sialosides has been achieved with exogenous N-acyl mannosamines, the metabolic precursor of SA.
18 However, this approach is limited by low cell type-or tissue-specicity, as demonstrated by broad expression of metabolically synthesized SA in different tissues from supplemented N-acyl mannosamines in animals.
19 In contrast, SA-FITC displays a high tendency to recognize liver tumors in mice.
12 Albeit preferentially and quickly accumulating in tumors in mice, SA-FITC undergoes quick in vivo clearance, leading to signicant uorescence-off within tumors. The distinct biomedical properties of SA-pNIR as compared to SA-FITC, e.g. long-term tumoral retention, clearly demonstrate the benecial effects of the pNIR moiety on in vivo tumor illumination. These observations reveal that the in vivo pharmacokinetics of sialic acid-conjugated theranostics could be effectively modulated with substituents of appropriate hydrophobicity (i.e. pNIR vs. FITC) at the C-9 position of sialic acid.
Cytotoxicity of SA-pNIR
Low toxicity is a prerequisite for imaging agents aimed at in vivo administration. We rst examined the effects of SA-pNIR on the survival of HeLa cells by trypan blue exclusion test. No obvious detrimental effects on cell viability were observed on cells treated with SA-pNIR for 24 h at doses up to 100 mg mL À1 (Fig. 8) , suggesting low cytotoxicity of SA-pNIR. To probe the systemic toxicity, SA-pNIR was injected into healthy mice by tail vein at doses of 150 mg kg
À1
. The mice were regularly monitored for adverse effects following injection. No signs of abnormality, including death, pain or fatigue, were observed in the probe-treated mice up to 10 days aer injection. Ex vivo analysis revealed low levels of NIR uorescence in the organs excised from the mice (ESI, † Fig. S5 and S6 ), suggesting that SApNIR could be effectively cleared from the body. Taken together, these results suggest that SA-pNIR is of low biotoxicity.
Acidic pH dependent photothermal effects of SA-pNIR
Reagents that could convert optical energy into cytotoxic heat are attractive tools for light-mediated photothermal tumor therapy.
7 As such, intense investigations have been devoted to the development of various NIR-absorbing nanomaterials.
7
Given long-standing concerns regarding the in vivo biosafety of nanoscaled materials, small molecule theranostics are suitable for in vivo studies, as demonstrated by the approval of indocyanine green dye (ICG) for clinical applications. Inspired by the emerging use of NIR dyes in photothermal therapy, 20 we proceeded to examine the capability of SA-pNIR as a pH-responsive photothermal agent. SA-pNIR was spiked into buffers of pH 7.5 and 4.5. The solutions were exposed to 660 nm laser illumination at a power density of 0.5 W cm À2 and the temperature of the solutions was monitored over the irradiation time. Fig. 9 clearly shows temperature elevation dependent on the acidic pH, demonstrating that SA-pNIR effectively converts NIR irradiation into heat in acidic media.
SA-pNIR mediated photothermal killing of cells
SA-pNIR was then evaluated for its photothermal effects on host cells. HeLa, U87-MG and Raw 264.7 cells pre-loaded with SApNIR or SA were either irradiated with an NIR laser, or not subjected to irradiation. The viability of these cell populations was assayed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT). Cells treated with SA-pNIR and light illumination display further decreased viability relative to that of cells treated with NIR laser irradiation or SA-pNIR alone (Fig. 10) , demonstrating the synergistic effects of SA-pNIR and light irradiation for detrimental effects on host cells. SA-pNIR has a maximal absorption at 715 nm (Fig. 1) . The molecular extinction coefficient at 715 nm is 2-fold higher than that at 660 nm. Given the suboptimal wavelength used for photothermal evaluation of SA-pNIR (660 nm, Fig. 9 and 10 ), it can be anticipated that the efficacy of SA-pNIR mediated photothermal killing of tumor cells could be further increased with an appropriate instrumental laser (715 nm).
Complete manual cytoreduction of small-sized or embedded tumor foci is oen challenging during surgery. Photothermal tumor ablation during surgery is applicable due to surgical exposure of cancerous tissues that are otherwise inaccessible to exogenous laser irradiation. Theranostics allowing intraoperative tumor staging and simultaneous photothermal tumor therapy are of clinical signicance to complement surgical dissection. The lysosomal acidity-triggered photothermal effect of SA-pNIR on targeted cells supports the potential utility of SApNIR as a theranostic probe for dual imaging and photothermal killing of tumor foci in intraoperative settings.
Conclusions
SA-pNIR, a sialylated lysosome-activatable NIR dye, has been developed for intraoperative tumor therapy. The sialic acid entity enables effective tumor targeting in mice and the NIR Fig. 8 Cytotoxicity of SA-pNIR. HeLa cells were cultured in DMEM containing various levels of SA-pNIR (0-100 mg mL
À1
) for 24 h. Cell number and cell viability were determined by trypan blue exclusion assay. ), or not subjected to irradiation, in fresh DMEM for 10 min, and then further cultured for 24 h. Cell viability was determined by MTT assay.
prouorophore undergoes lysosomal pH-triggered isomerization to give an NIR signal. In contrast with SA-FITC which is compromised by "always-on" green uorescence and quick in vivo clearance, SA-pNIR displays signal activation in viable tumor cells, high tumor-to-normal tissue signal contrasts, and long-term retention in tumors, rendering optical imaging over an adequate duration which is critical for practical surgical intervention. In addition, SA-pNIR effectively converts NIR irradiation into heat in acidic lysosomes and leads to obvious cell death upon NIR irradiation, suggesting its utility for photothermal ablation of surgically exposed tumor foci that are otherwise inaccessible to exogenous light. With superior in vivo pharmacokinetics, high performance tumor illumination, and acid-responsive photothermal properties, SA-pNIR is a promising small molecular theranostic for uorescence guided tumor detection and possibly photothermal tumor therapy in intraoperative settings.
